

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

INSIDE INFORMATION
RESULTS FORECAST FOR THE YEAR 2021

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

I. Results Forecast

A. Period of the results forecast

The period of the results forecast is from January 1, 2021 to December 31, 2021 (the “**Reporting Period**”).

B. Details of the results forecast

1. According to the preliminary estimation, the revenue of the Group for the year ended December 31, 2021 is expected to be RMB4,200.0 million to RMB4,400.0 million, representing an increase of 16,773.97% to 17,577.49% from approximately RMB24.9 million for the year ended December 31, 2020.
2. The net profit attributable to the shareholders of the Company for the year ended December 31, 2021 is expected to be RMB1,850.0 million to RMB2,000.0 million, while there was a net loss attributable to the shareholders of the Company of approximately RMB396.6 million for the year ended December 31, 2020. The Company achieved a turnaround from loss to profit for the year ended December 31, 2021.
3. The net profit attributable to the shareholders of the Company after deducting the non-recurring profit or loss for the year ended December 31, 2021 is expected to be RMB1,740.0 million to RMB1,880.0 million, while there was a net loss attributable to the shareholders of the Company after deducting the non-recurring profit or loss of approximately RMB511.3 million for the year ended December 31, 2020. The Company achieved a turnaround from loss to profit for the year ended December 31, 2021.

C. Preliminary audit of the results forecast

This results forecast has not been audited or reviewed by independent auditors.

II. Performance in the corresponding period in the last year

During the corresponding period in 2020, according to PRC Generally Accepted Accounting Principles, the revenue of the Group for the year ended December 31, 2020 was approximately RMB24.9 million, the net loss attributable to the shareholders of the Company was approximately RMB396.6 million; the net loss attributable to the shareholders of the Company after deducting non-recurring profit or loss was approximately RMB511.3 million.

III. Reasons for changes in results

A. *The impact of the vaccine businesses*

During the Reporting Period, the Company's Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia) was granted the conditional marketing authorization by the National Medical Products Administration in mainland China, and obtained the emergency use authorization in various foreign countries. As a result, the revenue and the net profit attributable to the shareholders of the Company further increased.

B. *The impact of the non-recurring profit or loss*

The impact was mainly due to the income from cash management of unutilized proceeds.

IV. Risk Factors

The Company does not have any significant uncertainty factors that may affect the accuracy of the results forecast.

V. Other Information

The results forecast above is only a preliminary calculation performed by the finance department of the Company and has not been audited or reviewed by the Company's independent auditors. The detail will be disclosed in the annual report of 2021. Investors are reminded to exercise caution when making investment decisions.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, January 28, 2022

As of the date of this announcement, the board of directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.